Home > Publications Database > CXCL13 in Cerebrospinal Fluid: Clinical Value in a Large Cross-Sectional Study. > print

001     266804
005     20240403131752.0
024 7 _ |a pmc:PMC10779058
|2 pmc
024 7 _ |a 10.3390/ijms25010425
|2 doi
024 7 _ |a pmid:38203597
|2 pmid
024 7 _ |a 1422-0067
|2 ISSN
024 7 _ |a 1661-6596
|2 ISSN
037 _ _ |a DZNE-2024-00056
041 _ _ |a English
082 _ _ |a 540
100 1 _ |a Erhart, Deborah Katharina
|0 0000-0002-3003-4119
|b 0
245 _ _ |a CXCL13 in Cerebrospinal Fluid: Clinical Value in a Large Cross-Sectional Study.
260 _ _ |a Basel
|c 2023
|b Molecular Diversity Preservation International
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1705566681_9223
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a C-X-C-motif chemokine ligand 13 (CXCL13) in cerebrospinal fluid (CSF) is increasingly used in clinical routines, although its diagnostic specificity and divergent cut-off values have been defined so far mainly for neuroborreliosis. Our aim was to evaluate the value of CSF-CXCL13 as a diagnostic and treatment response marker and its role as an activity marker in a larger disease spectrum, including neuroborreliosis and other neuroinflammatory and malignant CNS-disorders. Patients who received a diagnostic lumbar puncture (LP) (n = 1234) between July 2009 and January 2023 were included in our retrospective cross-sectional study. The diagnostic performance of CSF-CXCL13 for acute neuroborreliosis was highest at a cut-off of 428.92 pg/mL (sensitivity: 92.1%; specificity: 96.5%). In addition, CXCL13 levels in CSF were significantly elevated in multiple sclerosis with clinical (p = 0.001) and radiographic disease activity (p < 0.001). The clinical utility of CSF-CXCL13 appears to be multifaceted. CSF-CXCL13 is significantly elevated in patients with neuroborreliosis and shows a rapid and sharp decline with antibiotic therapy, but it is not specific for this disease and is also highly elevated in less common subacute neuroinfectious diseases, such as neurosyphilis and cryptococcal meningitis or in primary/secondary B-cell lymphoma.
536 _ _ |a 354 - Disease Prevention and Healthy Aging (POF4-354)
|0 G:(DE-HGF)POF4-354
|c POF4-354
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a CXCL13 protein, human
|2 NLM Chemicals
650 _ 7 |a CNS-inflammatory diseases
|2 Other
650 _ 7 |a CXCL13
|2 Other
650 _ 7 |a cerebrospinal fluid
|2 Other
650 _ 7 |a neuroborreliosis
|2 Other
650 _ 7 |a Chemokine CXCL13
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Cross-Sectional Studies
|2 MeSH
650 _ 2 |a Retrospective Studies
|2 MeSH
650 _ 2 |a Spinal Puncture
|2 MeSH
650 _ 2 |a Multiple Sclerosis
|2 MeSH
650 _ 2 |a Neurosyphilis
|2 MeSH
650 _ 2 |a Syndrome
|2 MeSH
650 _ 2 |a Chemokine CXCL13
|2 MeSH
700 1 _ |a Klose, Veronika
|0 P:(DE-2719)9001084
|b 1
700 1 _ |a Schäper, Tatjana
|b 2
700 1 _ |a Tumani, Hayrettin
|0 P:(DE-2719)9002007
|b 3
|u dzne
700 1 _ |a Senel, Makbule
|0 0000-0002-2737-7495
|b 4
770 _ _ |a Exploring Molecular Mechanisms of Inflammatory Diseases
773 _ _ |a 10.3390/ijms25010425
|g Vol. 25, no. 1, p. 425 -
|0 PERI:(DE-600)2019364-6
|n 1
|p 425
|t International journal of molecular sciences
|v 25
|y 2023
|x 1422-0067
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/266804/files/DZNE-2024-00056.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/266804/files/DZNE-2024-00056.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:266804
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)9001084
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 3
|6 P:(DE-2719)9002007
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-354
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Prevention and Healthy Aging
|x 0
914 1 _ |y 2023
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-08-25
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2023-07-07T16:31:47Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-08-25
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b INT J MOL SCI : 2022
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2023-07-07T16:31:47Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2023-07-07T16:31:47Z
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b INT J MOL SCI : 2022
|d 2023-08-25
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-08-25
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-08-25
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-08-25
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1150
|2 StatID
|b Current Contents - Physical, Chemical and Earth Sciences
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-08-25
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2023-07-07T16:31:47Z
920 1 _ |0 I:(DE-2719)1910005
|k AG Zhan
|l Neuroepidemiology
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1910005
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21